ArticleAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2017
Adoptive T-Cell Therapy for Solid Tumors.
Article in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.Frontiers in immunology · 2024Pooled it
- Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Harnessing immunity against breast cancer: from checkpoints to cell therapies.Journal of translational medicine · 2026Review
- Article
- CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.Cell reports. Medicine · 2025Review
- FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective.Molecular biotechnology · 2025Review
- CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors.Journal for immunotherapy of cancer · 2025Article
- The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy.Cancer metastasis reviews · 2024Review
- Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.Medical oncology (Northwood, London, England) · 2024Review
- Exogenous IL-2 delays memory precursors generation and is essential for enhancing memory cells effector functions.iScience · 2024Article
- A dual-luciferase bioluminescence system for the assessment of cellular therapies.Molecular therapy. Oncology · 2024Article
- Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.Cells · 2024Review
- Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice.Journal of gastrointestinal oncology · 2024Article
- Oncolytic virus and CAR-T cell therapy in solid tumors.Frontiers in immunology · 2024Review
- Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence.Science advances · 2023Article
- Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy.Pharmaceutics · 2023Article
- Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer.Journal for immunotherapy of cancer · 2023Review
- CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy.Cancers · 2023Review
- PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105.Heliyon · 2023Article
- Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.Oncology letters · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is an innovative form of immunotherapy wherein autologous T cells are genetically modified to express chimeric receptors encoding an antigen-specific single-chain variable fragment and various costimulatory molecules. Upon administration, these modified T cells traffic to, and recognize, cancer cells in an HLA-independent manner. CAR T-cell therapy has shown remarkable success in the treatment of CD-19-expressing B-cell acute lymphocytic leukemia. However, clinical gains to the same magnitude have not been reported in solid tumors. Several known obstacles to CAR T-cell therapy for solid tumors include target antigen identification, effective trafficking to the tumor, robust activation, proliferation, and in vivo cytotoxicity. Beyond these T-cell intrinsic properties, a complex and dynamic immunosuppressive tumor microenvironment in solid tumors hinders T-cell efficacy. Notable advancements in CAR design to include multiple costimulatory molecules, ligands, and soluble cytokines have shown promise in preclinical models, and some of these are currently in early-phase clinical trials. In this review, we discuss selected solid tumor malignancies and relevant preclinical data and highlight clinical trial results that are available. Furthermore, we outline some obstacles to CAR T-cell therapy for each tumor and propose strategies to overcome some of these limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.